GLP-1s are being promoted as breakthrough drugs for weight loss and diabetes. But their growing popularity is outpacing clarity around when, why, and how they should be covered. Many employers are asking questions like:
- Are we expected to offer these medications?
- What clinical evidence supports long-term use?
- How can we manage cost without denying care?
- What are other organizations doing—and what’s working?
Our report answers these questions and more. It offers insights for HR, finance, and benefits leaders who need to make tough decisions in an environment of rapid change.
